I-Sorafenib CAS 284461-73-0 Purity ≥99.0% (HPLC) API Factory High Quality
Ubonelelo ngezoRhwebo i-Sorafenib Tosylate kunye neziPhakathi eziNxulumeneyo:
I-Sorafenib Tosylate CAS: 475207-59-1
Sorafenib CAS: 284461-73-0
I-4-Chloro-N-Methyl-2-Pyridinecarboxamide CAS: 220000-87-3
I-4-(4-Aminophenoxy)-N-Methylpicolinamide CAS: 284462-37-9
I-4-Chloro-3-(Trifluoromethyl)phenyl Isocyanate CAS: 327-78-6
| Igama | I-Sorafenib |
| Izithethantonye | Isiseko sasimahla seSorafenib |
| Inombolo yeCAS | 284461-73-0 |
| Inombolo yeCAT | RF-API04 |
| Ubume beStokhwe | Kwi-Stock, iMveliso yeMveliso ukuya kumakhulu eeKilogram |
| Ifomula yeemolekyuli | I-C21H16ClF3N4O3 |
| Ubunzima beMolekyuli | 464.82 |
| Ukuxinana | 1.454±0.06 g/cm3 |
| Ukunyibilika | Inyibilika kwi-DMSO |
| Iimeko zokuthumela ngenqanawe | Ubushushu obugciniwe |
| Uphawu | Ruifu Chemical |
| Into | Iinkcukacha |
| Imbonakalo | Mhlophe ukuya kwi-Off-White Powder |
| Ubunyulu / Indlela yokuHlalutya | ≥99.0% (HPLC) |
| Ukuchongwa | H-NMR, MS |
| Ilahleko ekomisweni | ≤1.0% |
| Intsalela kwi-Ignition | ≤0.10% |
| Ukungacoceki Okukodwa | ≤0.20% (HPLC) |
| Ukungcola ngokupheleleyo | ≤1.0% (HPLC) |
| Iintsimbi ezinzima | ≤20ppm |
| Ukucaca kwesisombululo | Ukuhambelana noMgangatho |
| Umgangatho woVavanyo | Umgangatho woShishino |
| Ukusetyenziswa | I-RCC kunye ne-HCC |
Iphakheji: Ibhotile, ingxowa yefoyile yeAluminiyam, igubu lekhadibhodi, 25kg/Igubu, okanye ngokwemfuno yomthengi.
Imeko yoGcino:Gcina kwizikhongozeli ezivaliweyo kwindawo epholileyo neyomileyo;Khusela ekukhanyeni, ukufuma kunye nokuhlaselwa zizinambuzane.
I-Sorafenib Tosylate (i-CAS: 475207-59-1) luhlobo olutsha lwechiza le-antitumor ekujoliswe kulo, laphuhliswa yi-German Bayer Pharmaceuticals, kwaye yabonisa umsebenzi owandayo we-antitumor kwiimvavanyo zezilwanyana zangaphambili.I-Sorafenib ifumaneka kwiipilisi ze-200-mg zolawulo lomlomo kwaye isetyenziselwa unyango lwe-RCC kunye ne-HCC.I-Sorafenib Tosylate (i-CAS: 475207-59-1) inokuchaphazela ngaxeshanye iiseli ze-tumor kunye nemithambo yegazi ye-tumor.Inempembelelo ephindwe kabini ye-antitumor: inokuthintela iindlela zokudluliselwa komqondiso weseli elamlwa yi-RAF/MEK/ERK ukuthintela ngokuthe ngqo ukukhula kweseli yethumba, ngelixa ikwathintela i-VEGF kunye ne-platelet derived growth factor (PDGF) receptors ukuthintela ukubunjwa kwegazi elitsha lethumba. imikhumbi, ngaloo ndlela inqanda ngokungangqalanga ukukhula iseli ithumba.I-Sorafenib yi-inhibitor ye-Raf-1 kunye ne-B-RAF kunye nee-tyrosine kinases ezininzi.
